PARP3 Inhibitors
1 drugsAbout PARP3
PARP3, or poly(ADP-ribose) polymerase 3, is a protein involved in DNA repair and other cellular processes. While its exact function is still being researched, its role in DNA damage response makes it a potential target for cancer therapy.
Inhibiting PARP3 activity could disrupt DNA repair mechanisms in cancer cells, making them more susceptible to cell death. Currently, there is no genetic evidence data available linking PARP3 directly to specific diseases.
There is one FDA-approved drug, LYNPARZA (AstraZeneca), that targets PARP proteins and has 4 indications in oncology. LYNPARZA is a small molecule and was first approved in 2014.
Strategic Insights
ℹ️ How we calculate- Validated target with strong trial activity and 81% attractiveness score.
- White space opportunity in Metastatic Pancreatic Adenocarcinoma with only 5 trials.
Top PARP3 Drugs
AstraZeneca is the only company with an approved drug targeting PARP3.
High market concentration suggests significant entry barriers; consider strategic partnerships.
PARP3 Clinical Trials 344 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 119 | 48 | 18 | 52 | 73% |
| Phase 2 | 181 | 47 | 27 | 105 | 64% |
| Phase 3 | 39 | 15 | 2 | 22 | 88% |
| Phase 4 | 5 | 2 | 0 | 3 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
3 Phase 3 trials testing approved PARP3 drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting PARP3. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 2 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 308 clinical trials targeting PARP3.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities